Using cheminformatics to predict cross reactivity of “designer drugs” to their currently available immunoassays

Matthew D Krasowski1* and Sean Ekins2

Abstract

Background: A challenge for drug of abuse testing is presented by ‘designer drugs’, compounds typically discovered by modifications of existing clinical drug classes such as amphetamines and cannabinoids. Drug of abuse screening immunoassays directed at amphetamine or methamphetamine only detect a small subset of designer amphetamine-like drugs, and those immunoassays designed for tetrahydrocannabinol metabolites generally do not cross-react with synthetic cannabinoids lacking the classic cannabinoid chemical backbone. This suggests complexity in understanding how to detect and identify whether a patient has taken a molecule of one class or another, impacting clinical care.

Methods: Cross-reactivity data from immunoassays specifically targeting designer amphetamine-like and synthetic cannabinoid drugs was collected from multiple published sources, and virtual chemical libraries for molecular similarity analysis were built. The virtual library for synthetic cannabinoid analysis contained a total of 169 structures, while the virtual library for amphetamine-type stimulants contained 288 compounds. Two-dimensional (2D) similarity for each test compound was compared to the target molecule of the immunoassay undergoing analysis.

Results: 2D similarity differentiated between cross-reactive and non-cross-reactive compounds for immunoassays targeting mephedrone/methcathinone, 3,4-methylenedioxyxymethamphetamine, benzylpiperazine, mephentermine, and synthetic cannabinoids.

Conclusions: In this study, we applied 2D molecular similarity analysis to the designer amphetamine-type stimulants and synthetic cannabinoids. Similarity calculations can be used to more efficiently decide which drugs and metabolites should be tested in cross-reactivity studies, as well as to design experiments and potentially predict antigens that would lead to immunoassays with cross reactivity for a broader array of designer drugs.

Keywords: Amphetamines, Cannabinoids, Molecular models, Similarity, Toxicology

Background

Immunoassays (antibody-based assays) are widely employed for drug of abuse/toxicology screening on urine or other bodily fluids. Immunoassays may utilize polyclonal or monoclonal antibodies, with a trend towards monoclonal antibody-based designs [1,2]. Many hospital-based clinical laboratories perform immunoassay drug of abuse screening panels targeted towards commonly abused drugs or drug classes such as amphetamines, benzodiazepines, cannabinoids, cocaine, methadone, opiates, and phencyclidine [3,4]. In addition to immunoassays, mass spectrometry-based methods such as gas chromatography/mass spectrometry (GC/MS) or liquid chromatography-tandem mass spectrometry (LC/MS/MS) can provide specific and definitive identification of drugs and drug metabolites; such methods are often used for confirmation of positive immunoassay screening results or for detection of drugs known to be undetectable or not readily detected by immunoassays [4-6]. While an increasing number of clinical laboratories are using mass spectrometry-based assays for drug of abuse testing, relatively few hospital-based clinical laboratories have the capability to do this testing with a rapid turnaround time. Thus, many clinical laboratories refer confirmatory testing to off-site regional or
commercial reference laboratories, such that the turn-
around time is too slow to aid in real-time patient man-
agement [3,4]. Consequently, immunoassays continue to
be used in many settings for drug of abuse testing.

A challenge for drug of abuse testing is presented by
what are widely termed ‘designer drugs’, a heterogeneous
group of psychoactive compounds typically discovered
by modifications of existing clinical drug classes such as
amphetamines [7-10]. Two current categories of de-
signer drugs are the amphetamine-type stimulants and
the synthetic cannabinoids, each of which comprises a
chemically diverse set of compounds (see Figures 1 and 2
for representative compounds and their chemical struc-
tures). Designer drugs may be sold over the counter or via
the internet using deceptive descriptors such as “plant
fertilizer”, “incense”, “potpourri”, “research chemicals”, or
“bath salts”. Further, many compounds are initially legal
due to the regulatory challenge of trying to outlaw the
large numbers of possible drug analogs that may be syn-
thesized and distributed; authorities throughout the world
have struggled with this issue [11,12]. In 2011, the United
States Drug Enforcement Agency (DEA) temporarily
classified mephedrone, 3,4-methylenedioxypyrovalerone
(MDPV), and methylone as Schedule 1 drugs, a designa-
tion that indicates drugs with no accepted medical use
and very high abuse liability [13]. Additionally, in June of
2012, the United States Congress approved Schedule 1
status for an additional 26 designer amphetamine-type
stimulants and synthetic cannabinoids [14]. Clearly, due
to the diversity of amphetamine-type and cannabinoid
chemistry, there are likely many more structures that
will ultimately require restricted status.

The amphetamine-type stimulants are related to am-
phetamine, methamphetamine, and 3,4-methylenedioxy-
N-methylamphetamine (MDMA; “ecstasy”) [15]. Designer
amphetamine-type drugs represent hundreds of individual
compounds (many of which have detailed descriptions of
chemical synthesis and psychoactive effects in two books
by Shulgin and Shulgin [16,17]) and can be further broken
down into sub-categories such as β-keto amphetamines,
piperazines, tryptamines, and 2C compounds (see Figure 1
for examples). Methylone, MDPV, and mephedrone are

![Figure 1 Representative chemical structures of amphetamine-type drugs. Abbreviations: MDMA, 3,4-methylenedioxo-N-methylamphetamine; MDPV, 3,4-methylenedioxopyrovalerone; MDPBP, 3’,4’-methylenedioxy-a-pyrrolidinobutylphenone. Additional descriptions of compounds are in Additional file 1.](image-url)
the three most common amphetamine-like drugs currently referred to as “bath salts” and have received the most interest from the media and law enforcement [18,19].

The synthetic cannabinoids are similarly diverse and were originally examined for scientific and therapeutic applications (see Figure 2 for representative chemical structures) [20-22]. Like tetrahydrocannabinol (THC) from cannabis, the synthetic cannabinoids interact with cannabinoid receptors in the nervous system, producing a variety of psychoactive effects [23]. However, clandestine laboratories began to synthesize synthetic cannabinoids for use in products often marketed as “legal highs” [24]. Two of the most commonly abused synthetic cannabinoids are 1-naphthyl-(1-pentylindol-3-yl)methanone (JWH-018; named after discoverer John W. Huffman) and 2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl) (JWH-250) [25]. As shown in Figure 2, some synthetic cannabinoids such as JWH-018 (a naphthoylindole) differ considerably in chemical structure from the “classic” cannabinoid chemical backbone of THC, while other compounds such as HU-210 (1,1-dimethylheptyl-11-hydroxy-THC) are analogs of THC.

Detection of designer amphetamine-type stimulants and synthetic cannabinoids in the clinical and forensic toxicology settings presents a complicated challenge [15]. There is a growing literature on detection of these designer molecules by mass spectrometry-based methods (see for example [26-40]). Drug of abuse screening immunoassays based on amphetamine, methamphetamine, and/or MDMA as the target molecule(s) cross-react with only a small subset of designer amphetamine-like drugs and are thus unreliable for detection of designer amphetamine-like drugs [41-45]. Immunoassays designed for THC metabolites (e.g., 11-nor-Δ9 THC-9-carboxylic acid, “9-carboxy-
THC”) generally do not cross-react with the synthetic cannabinoids that do not share the classic cannabinoid backbone found in THC [15]. This suggests complexity in understanding how to detect and correctly identify whether a patient has taken a molecule of one class or another, and this ultimately impacts clinical care.

Recently, enzyme-linked immunosorbent assays (ELISAs) for “bath salts” [45] and synthetic cannabinoids [46] have been developed and analyzed for cross-reactivity. The use of immunoassays such as ELISA for detection of designer drugs raises the question of how well such assays will detect a variety of compounds while avoiding false positives caused by cross-reactivity with unrelated compounds.

Two-dimensional (2D) molecular similarity analysis represents one of many potential cheminformatics approaches to this problem. In four previous publications, we provided proof of concept for the use of computational 2D or 3D similarity methods to predict cross-reactivity of compounds for immunoassays used for drug of abuse screening [44,47,48] and therapeutic drug monitoring [49] immunoassays. In these studies, 2D similarity using MDL keys/fingerprints were superior to 2D similarity using FCFP_6 fingerprints (one of many fingerprint types) and 3D pharmacophores in predicting cross-reactivity of immunoassays [44,47-49]. By comparing empirical data obtained from cross-reactivity studies with the molecular modeling studies, our published data indicate that 2D molecular similarity methods perform well in predicting cross-reactivity of drugs to existing drug of abuse screening immunoassays. Further, these methods can help prioritize compounds for cross-reactivity testing and identify novel cross-reacting compounds [48]. In this study, we now apply 2D molecular similarity analysis to the designer amphetamine-type stimulants and synthetic cannabinoids.

**Results**

**Similarity analysis of amphetamine-like drugs**

Mephedrone (4-methylmethcathinone) and MDPV are two common designer amphetamine-like drugs. Randox markets one ELISA assay targeting mephedrone/methcathinone and another assay targeting MDPV. Figure 3A shows the 2D similarity of methcathinone to 287 other amphetamine-like drugs (note: mephedrone and methcathinone have 2D similarity of 1.0 to each other due to how close they are in structure; see Additional file 1 for complete similarity and cross-reactivity data). The only molecules with 2D similarity of 0.6 or greater to methcathinone are other cathinone derivatives (e.g., methylmethcathinone, 3-fluoromethcathinone). The 2C and tryptamine series of drugs all possess 2D similarity of less than 0.4 to methcathinone. Figure 3B shows the 2D similarity of compounds with cross-reactivity > 0.8% of methcathinone in the Randox Mephedrone/Methcathinone assay (cross-reactivity data is from both the assay package insert and publication by Swortwood et al. [45]) compared to non-cross-reactive compounds. None of the 2C and tryptamine compounds tested cross-react with the mephedrone/methcathinone ELISA. Six of the eight cross-reactive compounds have 2D similarity to methcathinone of greater than 0.68, whereas only two of twenty-five non-cross-reactive compounds have 2D similarity that high. Figure 3B also shows 2D similarity to methcathinone of the “untested” compounds (i.e., those compounds in Additional file 1 whose cross-reactivity has not been reported). Figure 3C shows ROC curve analysis of how well 2D similarity as a “diagnostic test” predicts cross-reactivity of compounds for the Mephedrone/Methcathinone assay. The area under the curve (AUC) is 0.942.

Figure 3D shows the 2D similarity of MDPV to 287 other amphetamine-like drugs (complete dataset is in Additional file 1). Only 23 other compounds in this dataset possess 2D similarity of 0.6 or greater to MDPV. Only four compounds (other than MDPV itself) cross-react with the Randox MDPV ELISA (cross-reactivity data is from both the assay package insert and publication by Swortwood et al. [45]). Figure 3E shows the 2D similarity of compounds with cross-reactivity > 0.8% of methcathinone in the Randox MDPV assay. All four cross-reacting compounds have 2D similarity greater than 0.6 to MDPV. Figure 3E also shows 2D similarity to MDPV of “untested” compounds. Figure 3F shows the ROC curve analysis of how well 2D similarity predicts cross-reactivity of compounds for the MDPV assay. The AUC is 0.987. Table 1 lists true positives, false positives, true negatives, and false negatives at select cutoffs for the assays depicted in Figure 3.

Benzylpiperazin and mephentermine are two amphetamine-like drugs that may be abused [7,15]. Neogen markets separate ELISA assays for these two drugs. Figure 4A shows the 2D similarity of benzylpiperazine to 287 other amphetamine-like drugs (complete dataset is in Additional file 1). The only compounds with 2D similarity of 0.6 or greater are other piperazines, a single tryptamine compound (N,N-tetramethylenetryptamine), and phencyclidine. Of compounds tested for cross-reactivity, only two piperazine compounds (other than benzylpiperazine itself) cross-react with the Neogen Benzylpiperazine ELISA (Figure 4B; cross-reactivity data is from both the assay package insert and publication by Swortwood et al. [45]).

Figure 4C shows the 2D similarity of mephentermine to 287 other amphetamine-like drugs (complete dataset is in Additional file 1). The only compounds with 2D similarity to mephentermine of 0.6 or greater are phentermine, methamphetamine, amphetamine, p-methoxyethylamphetamine, 4-methylothioamphetamine, and ethylamphetamine. Only two compounds (methamphetamine and MDMA) cross-react with the Neogen Mephentermine
ELISA (Figure 4D). Both of these compounds have 5% or less cross-reactivity relative to mephentermine [45]. MDMA cross-reacts but has low 2D similarity (0.421).

Table 1 lists true positives, false positives, true negatives, and false negatives at select cutoffs for the assays depicted in Figure 4.

Similarity analysis of synthetic cannabinoids

The synthetic cannabinoids are a diverse group of molecules with a nomenclature that can be confusing. Hundreds of compounds are in the JWH (John W. Huffman) series, although many have not yet been identified as drugs of abuse [22,24,25]. Additional file 2 has 43 JWH...
compounds of known toxicologic importance, along with 32 associated metabolites. Even within the JWH series are different classifications including naphthoylindoles (e.g., JWH-018), naphthylmethylindoles (e.g., JWH-175), and phenylacetylindoles (e.g., JWH-201). There are several other series of synthetic cannabinoids including the AM, UR, RCS, and XLR series; some of these are closely related to compounds in the JWH series [24,25].

Figure 5 shows plots of the 2D similarity of 168 other compounds compared to four cannabinoid targets, with

Table 1 True positives, false positives, true negatives, and false negatives for the immunoassays using selected 2D similarity cutoffs

| Assay                        | 2D similarity cutoff | True positives | False positives | True negatives | False negatives |
|------------------------------|----------------------|----------------|-----------------|----------------|-----------------|
| Randox Mephedrone/Methcathinone | 0.680               | 6              | 2               | 25             | 2               |
|                              | 0.390               | 8              | 6               | 19             | 0               |
| Randox MDPV                  | 0.630               | 5              | 0               | 30             | 0               |
| Neogen Benzylpiperazine      | 0.730               | 3              | 1               | 28             | 0               |
| Neogen Mephentermine         | 0.840               | 2              | 0               | 26             | 1               |
|                              | 0.420               | 3              | 7               | 19             | 0               |
| JWH-018 Direct ELISA         | 0.673               | 27             | 21              | 44             | 3               |
| JWH-250 Direct ELISA         | 0.875               | 3              | 0               | 92             | 0               |
| Immunalysis MKT-1030         | 0.673               | 13             | 0               | 6              | 4               |
| Immunalysis MKT-1032         | 0.673               | 15             | 0               | 3              | 4               |
| Neogen Synthetic Cannabinoids| 0.673               | 23             | 0               | 4              | 8               |

Figure 4 Similarity analyses of benzylpiperazine (BZP) and mephentermine and prediction of immunoassay cross-reactivity. (A) 2D similarity of BZP to 287 amphetamine-like compounds. (B) 2D similarity of compounds that are cross-reactive, non-cross-reactive, or untested for the Neogen Benzylpiperazine Forensic ELISA. (C) 2D similarity of mephentermine to 287 amphetamine-like compounds. (D) 2D similarity of compounds that are cross-reactive, non-cross-reactive, or untested for the Neogen Mephentermine Forensic ELISA.
test compounds divided into broad categories [(i) JWH series, (ii) AM/UR/RCS/XLR series, (iii) all other synthetic cannabinoids not possessing the classic cannabinoid backbone of THC, (iv) cannabinoids sharing classic cannabinoid backbone of THC, (v) endogenous eicosanoid cannabinoids, and (vi) non-cannabinoids]. Figure 5A-C uses metabolites of JWH-018, JWH-073, and JHW-250, respectively, as target molecules for the 2D similarity analysis. These metabolites were chosen because they are detected well by at least one commercial immunoassay for which cross-reactivity data is available (some compounds are the calibrator for the assay). Figure 5D uses 9-carboxy-THC as the target compound for 2D similarity analysis.

Figure 5A shows 2D similarity analysis using the N-pentanoic acid metabolite of JWH-018 (calibrator compound for the Immunoanalysis MKT-1030 and MKT-1032 assay kits) as the target. Within the JWH series (including metabolites), all but one other compound (JWH-175) have 2D similarity to the JWH-018 metabolite of 0.6 or greater. Outside the JWH series, a number of other compounds have high similarity. These include the N-4-hydroxy metabolite of AM-2201 (similarity = 0.851) and WIN 55,212-2/WIN 55,212-3 (both have similarity = 0.638). The compounds closely related to THC have low 2D similarity to the JWH-018 metabolite, as do the two endogenous cannabinoids (all with 2D similarity less than 0.420). A similar pattern is seen in Figure 5B with the JWH-073 N-butanoic acid metabolite (a metabolite detected well by the Immunoanalysis MKT-1030 and MKT-1032 kits). Figure 5C shows the 2D similarity to the N-4-hydroxy metabolite of JWH-250 (a calibrator for a JWH-250 ELISA that has been described in a publication by Arntson et al. [46]). The overall pattern of similarity is roughly that of JWH-018 and JWH-073 in Figure 5A and 5B, with the exception that pravadoline, metabolites of RCS-4, and cannabipiperidiethanone have high similarity to the JWH-250 metabolite (see Figure 2 for chemical structures). Figure 5D shows similarity of 9-carboxy-THC to 168 other compounds. Outside of compounds sharing the classic cannabinoid backbone of THC, the THC metabolite has generally low similarity to other cannabinoids. CB-25 and CB-52, which are in essence hybrids of THC and the endogenous cannabinoid anandamide, possess low 2D similarity (0.407 and 0.400, respectively) despite sharing some core features with THC.
Figure 6A shows cross-reactivity data of a JWH-018 ELISA which uses the 5-hydroxy metabolite of JWH-018 as the calibrator [46]. Using the published cross-reactivity data, the 2D similarity to the JWH-018 metabolite is displayed in Figure 6A for compounds with 25% or more cross-reactivity, 1-24% cross-reactivity, less than 1% cross-reactivity, or “untested” (i.e., using all remaining compounds from Additional file 2). All compounds with 1% or more cross-reactivity have similarity to the JWH-018 metabolite of 0.623 or greater. In contrast, similarity of 0.623 or higher was seen in only 30 of the 65 compounds that displayed cross-reactivity less than 1%. Figure 6B shows the ROC curve analysis of how well 2D similarity performed as a “diagnostic test” predicting cross-reactivity of the JWH-018 ELISA. The AUC is 0.859. Figure 6C shows cross-reactivity data of a JWH-250 ELISA which uses the 4-hydroxy metabolite of JWH-250 as the calibrator [46]. In this assay, only three metabolites other than the calibrator had cross-reactivity greater than 1%. The lowest 2D similarity for these three cross-reactive compounds was 0.875. Table 1 lists true positives, false positives, true negatives, and false negatives at select cutoffs for the assays depicted in Figure 6.

Figure 6A shows cross-reactivity data of a JWH-018 ELISA which uses the 5-hydroxy metabolite of JWH-018 as the calibrator [46]. Using the published cross-reactivity data, the 2D similarity to the JWH-018 metabolite is displayed in Figure 6A for compounds with 25% or more cross-reactivity, 1-24% cross-reactivity, less than 1% cross-reactivity, or “untested” (i.e., using all remaining compounds from Additional file 2). All compounds with 1% or more cross-reactivity have similarity to the JWH-018 metabolite of 0.623 or greater. In contrast, similarity of 0.623 or higher was seen in only 30 of the 65 compounds that displayed cross-reactivity less than 1%. Figure 6B shows the ROC curve analysis of how well 2D similarity performed as a “diagnostic test” predicting cross-reactivity of the JWH-018 ELISA. The AUC is 0.859. Figure 6C shows cross-reactivity data of a JWH-250 ELISA which uses the 4-hydroxy metabolite of JWH-250 as the calibrator [46]. In this assay, only three metabolites other than the calibrator had cross-reactivity greater than 1%. The lowest 2D similarity for these three cross-reactive compounds was 0.875. Table 1 lists true positives, false positives, true negatives, and false negatives at select cutoffs for the assays depicted in Figure 6.

Figure 7A and 7C show cross-reactivity of the Immunoassays MKT-1030 and MKT-1032 synthetic cannabinoid assays, respectively, sorted by 2D similarity to the N-pentanoic acid metabolite of JWH-018 (calibrator for the assays). The highest 2D similarity of the non-cross-reactive compounds reported in the MKT-1030 and MKT-1032 package inserts to the JWH-018 metabolite was 0.667. For MKT-1030, only 1 of 14 compounds with 25% or more cross-reactivity and 2 of 12 compounds with 1-24% cross-reactivity had 2D similarity of 0.667 or lower (Figure 7A). For the MKT-1032 assay, only 4 of 18 compounds with 25% or more cross-reactivity had 2D similarity of 0.667 or lower (Figure 7C). Figure 7B shows the ROC curve analysis of how well 2D similarity performed as a diagnostic test predicting cross-reactivity of the MKT-1030 assay.
Figure 7D shows data for the Neogen Synthetic Cannabinoids assay. For this assay, the highest 2D similarity of the non-cross-reactive compounds to the N-pentanoic acid metabolite of JWH-018 was 0.667. Only 4 of 24 compounds with 50% or more cross-reactivity had a 2D similarity that low. 3-(1-naphthoyl)-1H-indole was unusual in having low 2D similarity to the JWH-018 metabolite (0.455) yet was cross-reactive in the Neogen and...
Figure 7 shows data for the Randox Synthetic Cannabinoids (Spice) ELISA kit. In this assay, all cross-reactive compounds had 2D similarity to the N-pentanoic acid metabolite of JWH-018 of 0.650 or higher. Only 2 of 7 non-cross-reactive compounds had similarity that high. Figure 7 also includes 2D similarity comparisons to untested compounds found in Additional file 2. Table 1 lists true positives, false positives, true negatives, and false negatives at select cutoffs for the assays depicted in Figure 7.

Discussion

Previously we have shown in several studies that 2D molecular similarity methods perform well in predicting cross-reactivity of drugs to existing drug of abuse screening immunoassays [44,47-49]. In this study, we have compared published empirical data obtained from various cross-reactivity studies using MDL keys and 2D molecular similarity data in order to illustrate that such cheminformatics studies can predict cross-reactivity of designer amphetamine-type stimulants and synthetic cannabinoids. We have also been able to measure molecular similarity for many more compounds than have been tested experimentally for assay cross-reactivity including a large dataset of FDA approved drugs and their metabolites. In general, these compounds display 2D similarities below those of compounds cross-reactive with the immunoassays. We propose that molecular similarity can help differentiate between likely cross-reactive and non-cross reactive compounds to immunoassays for methcathinone/mephedrone, MDPV, and synthetic cannabinoids. This could be useful for selecting and classifying additional compounds that may also require DEA Schedule I status classification [13,14].

The evaluation and application of cheminformatics approaches to this research area has been limited [44,47-49]. We have previous compared FCFP_6 fingerprints (one of many fingerprint types) and 3D pharmacophores with MDL keys/fingerprints [44,48,49]. The goal of the current study was not to perform an exhausting analysis of fingerprints or similarity measures. Future studies could evaluate commercial and open source fingerprints (some of which may encode 3D information) as well as approaches to normalize, standardize, or combine data from different approaches using methods such as the belief theory [50] or data fusion [51-54]. In addition, approaches other than ROC curves could be used to evaluate the similarity and experimental cross-reactivity data [55].

A limitation of the similarity approaches is that these cannot account for the complex three-dimensional molecular interactions inherent in antibody-antigen binding. 3-(1-naphthyl)-1H-indole is an example of a compound with low 2D similarity to the target compounds of an immunoassay, but which nonetheless has good cross-reactivity. 3-(1-naphthyl)-1H-indole possesses the same overall shape as the JWH series of compounds but is missing a nitrogen atom along with the aliphatic tail (Figure 2). Compounds such as 3-(1-naphthyl)-1H-indole may provide insight into the minimal sub-structural features important for antibody-drug interactions. An additional limitation of the similarity methods are that these do not account for concentration-dependence of cross-reactivity. There is very limited data on pharmacokinetics of synthetic cannabinoids and amphetamine-type drugs, especially at doses used to achieve intoxication. Even compounds with low cross-reactivity may be detected by an assay if present in urine or other body fluid at high concentrations.

As more experimental cross-reactivity data is generated for each immunoassay, it may be possible to use this to build machine learning models (e.g., Bayesian or Support Vector Machine) in order to predict this property for a new compound. The advantage of this approach is that it is not dependent on molecular similarity to a single molecule but instead uses the empirical data for a range of compounds for that subject of the immunoassay.

Experimental

Cross-reactivity data

Cross-reactivity data was found in multiple sources including published literature and package inserts for marketed assays. Randox Toxicology Limited (Crumlin, Antrim, United Kingdom) markets two ELISA kits for presumptive identification of “bath salts”, one targeting mephedrone/methcathinone (Mephedrone/Methcathinone ELISA, product # MD3475) and the other directed at detection of MDPV (MDPV ELISA, product # MD3476). Randox also markets an ELISA assay for synthetic cannabinoids [Synthetic Cannabinoids (Spice) ELISA, product # SC3474]. Immunalysis, Inc. (Pomona, CA, USA) markets two assays for synthetic cannabinoids [K2 (Synthetic Cannabinoids-1) Direct ELISA kit, product # MKT-1030; and Synthetic Cannabinoids (Spice, K2) Homogeneous Enzyme Immunoassay (HEIA), product # MKT-1032]. Neogen Corporation (Lexington, KY, USA) markets ELISAs for synthetic cannabinoids [Synthetic Cannabinoids (SPICE) ELISA kit], benzylpiperazine (Benzylpiperazine Forensic ELISA), and mephentermine (Mephentermine Forensic ELISA). Two publications report extensive cross-reactivity testing of immunoassays targeted at synthetic cannabinoids [46] and amphetamine-type stimulants [45].

For the Neogen Synthetic Cannabinoids ELISA, Randox Synthetic Cannabinoids ELISA, the Immulanalysis synthetic cannabinoids assays, and two synthetic cannabinoids assays reported in the literature by Arntson et al. [46], there is extensive cross-reactivity data covering a wide range of values. Following an approach used in our
previous publications [44,47-49], we have divided the data for these assays in different groups based on degree of cross-reactivity. The exact subdivisions are somewhat arbitrary (especially given the wide and varying numeric cross-reactivity values for these assays) but do provide a relative scale of strong versus weak cross-reactivity. All data is presented in dot plots that allow for visualization of the entire set of data.

Virtual chemical libraries
The virtual chemical libraries (Additional files 1 and 2) used for molecular similarity analysis were built using parent drugs and metabolites identified in the package inserts and literature references cited in the previous paragraph and from additional published literature on pharmacokinetics of amphetamine-type stimulants [44,56-62] and synthetic cannabinoids [25,30,33,40,63-69]. The virtual library for synthetic cannabinoid analysis contained a total of 169 structures (including two endogenous eicosanoid cannabinoids — anandamide and 2-arachidonoylglycerol [70,71]); and (ten non-cannabinoids which have been tested for cross-reactivity in synthetic cannabinoid immunoassays [46]). The virtual library for amphetamine-type stimulants contained 288 compounds. Many of the amphetamine-type stimulants are described in two books by Shulgin and Shulgin [16,17] and the number used in these books is also included in Additional file 1 for cross-reference. Also included in the virtual chemical library was a database of Food and Drug Administration (FDA)-approved drugs (n = 676) derived from the Clinician’s Pocket Drug Reference [72], supplemented with drugs of abuse and drug metabolites (n = 110). This database has been used in four of our previous publications [48,49,73,74].

Conclusions
In conclusion, we propose that similarity calculations can be used to more efficiently decide which drugs and metabolites should be tested in cross-reactivity studies, as well as to design experiments and potentially predict antigens that would lead to immunoassays with cross-reactivity for a broader array of designer drugs. As new analogs are synthesized and distributed, similarity calculations can guide and prioritize cross-reactivity studies. This very basic method may form the foundation for applying more complex cheminformatics approaches as more immunoassay cross-reactivity data is generated.

Methods
2D molecular similarity analysis
Comparison of similarity of test molecules to the target compounds of the immunoassays in question used 2D similarity analysis, which determines the similarity between molecules independent of any in vitro data

Statistical analysis
Statistical analyses using receiver operating characteristic (ROC) curve analysis were carried out in EP Evaluator release 9 (Data Innovations, South Burlington, VA, USA). Sensitivity was defined as: (number of true positives)/(number of true positives + number of false negatives). Specificity was defined as: (number of true negatives)/(number of true negatives + number of false positives). Efficiency was defined as: (number of true positives + number of true negatives)/(number of true positives + number of true negatives + number of false positives + number of false negatives). ROC curve analysis plots the true positive rate (sensitivity) on the y-axis versus the false positive rate (1-specificity). EP Evaluator calculates the true and false positive rate at a range of thresholds for the 2D similarity in discriminating experimental determined assay cross-reactivity (positive) compared to lack of cross-reactivity (negative). ROC curve analysis was only performed if there were five or more cross-reactive compounds for a given assay. EP Evaluator does not allow for ROC curve analysis if less than five datapoints are available in either the positive or negative groups. This is to avoid erroneous conclusions based on ROC curve analysis of samples with small study size [78].

Additional files
Additional file 1: Cross-Reactivity and Similarity Data for Amphetamine-like Compounds: Contains common and scientific names and SMILES identifiers for compounds, along with cross-reactivity data of immunoassays and 2D similarity measures for the amphetamine-like compounds analyzed in this study.
Additional file 2: Cross-Reactivity and Similarity Data for Cannabinoids: Contains common and scientific names and SMILES identifiers for compounds, along with cross-reactivity data of immunosassays and 2D similarity measures for the cannabinoid compounds analyzed in this study.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MDK and SE conceived and designed the experiments and analyzed the data. MDK wrote the initial manuscript. Both authors read and approved the final manuscript.

Acknowledgements
SE thanks Accelrys, Inc. for kindly providing Discovery Studio software.

Author details
1Department of Pathology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA. 2Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina, NC 27526, USA.

Received: 27 January 2014 Accepted: 7 May 2014
Published: 10 May 2014

References
1. George S: Position of immunological techniques in screening in clinical toxicology. Clin Chem Lab Med 2004, 42:1288–1309.
2. Melanson SE: The utility of immunosassays for urine drug testing. Clin Lab Med 2012, 32:429–447.
3. Hamnett-Stabler CA, Pesce AJ, Cannon DJ: Urine drug screening in the medical setting. Clin Chim Acta 2002, 315:125–135.
4. Moeller KE, Lee KC, Kissack JC: Urine drug screening: practical guide for clinicians. Mayo Clin Proc 2008, 83:66–76.
5. Tenore PL: Advanced urine toxicology testing. J Addict Dis 2010, 29:436–448.
6. Wu AH, Gerona R, Armenian P, French D, Petrie M, Lynch KL: Role of liquid chromatography-high-resolution mass spectrometry (LC-HR/MS) in clinical toxicology. Clin Toxicol (Phila) 2012, 50:733–742.
7. Christoffersen KS: Amphetamine designer drugs – an overview and epidemiology. Toxicol Lett 2000, 112–113:127–131.
8. Cottenin O, Rolland B, Karila L: New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature. Curr Pharm Des 2013, 2013:2013. In press.
9. Gunderson EM: Synthetic Cannabinoids: A New Frontier of Designer Drugs, Ann Intern Med 2013, 159:563–564.
10. Zawilski JB, Wojcieszak J: Designer cathinones—an emerging class of novel recreational drugs. Forensic Sci Int 2013, 231:42–53.
11. Kapka-Skrzypczak L, Kulpa P, Sawicki K, Woltyla A, Krasowski M: Legal highs - legal aspects and legislative solutions. Ann Agric Environ Med 2011, 18:304–309.
12. King LA: Legal controls on cannabinoids: An international dilemma? Drug Test Anal 2013, 6:80–87.
13. United States Department of Justice: Schedules of controlled substances: temporary placement of three synthetic cannabinoids into Schedule I. Final order. Fed Regist 2013, 78:28735–28793.
14. Congress agrees to add 26 synthetic drugs to Controlled Substances Act: http://www.justice.gov/dea/pubs/pressrel/po361912.html.
15. Peters FT, Martinez-Ramirez JA: Analytical toxicology of emerging drugs of abuse. Ther Drug Monit 2010, 32:532–539.
16. Shulgin A, Shulgin A: PiHKAL: A Chemical Love Story. Berkeley, CA: Transform Press; 1991.
17. Shulgin A, Shulgin A: TiHKAL: The Continuation. Berkeley, CA: Transform Press; 1997.
18. Ross EA, Watson M, Goldberger B: "Bath salts" intoxication. N Engl J Med 2011, 365:967–968.
19. Winder GS, Stem N, Hosangar A: Are "Bath Salts" the next generation of stimulant abuse? J Subst Abuse Treat 2012, 44:42–45.
20. Huffman JW, Dai D: Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg Med Chem 1996, 4:563–566.
21. Shanks KG, Dahn T, Terrell AR: Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework. J Anal Toxicol 2012, 36:145–152.
22. Vardakou I, Pistos C, Spiliopoulos C: Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010, 197:157–162.
23. Pacher P, Kunos G: Modulating the endocannabinoid system in human health and disease—successes and failures. PLoS J 2013, 280:1918–1943.
24. Seely KA, Lapoint J, Moran JH, Fattore L: Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 2012, 39:234–243.
25. Brents LK, Prather PL: The K2/Spice Phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev 2014, 46:72–85.
26. Al-Saffar Y, Stephenson NN, Beck O: Multicomponent LC-MS/MS screening method for detection of new psychoactive drugs, legal highs, in urine-Experience from the Swedish population. J Chromatogr B Analyt Technol Biomed Life Sci 2013, 930:112–120.
27. Bell C, George C, Kornan AT, Traynor A: Development of a rapid LC-MS/MS method for direct urinalysis of designer drugs. Drug Test Anal 2011, 3:494–504.
28. Dresen S, Kneisel S, Weinmann W, Zimmermann R, Auwaerter V: Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanamidine in serum and its application to forensic samples. J Mass Spectrom 2011, 46:163–171.
29. Dzadosz M, Weller JP, Kintischar M, Teske J: Scheduled multiple reaction monitoring algorithm as a way to analyse new designer drugs combined with synthetic cannabinoids in human serum with liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2013, 928:84–89.
28. Elsholy MA, Gul W, Elsholy KM, Murphy TP, Madaqul VA, Khan SI: Liquid chromatography-tandem mass spectrometry analysis of urine specimens for K2 (JWH-018) metabolites. J Anal Toxicol 2011, 35:487–495.
30. Hutter M, Kneisel S, Auwaerter V, Neukamm MA: Determination of 22 synthetic cannabinoids in human hair by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2012, 903:95–101.
31. Kacinko SL, Xu A, Homan JW, McMullin MM, Warrington DM, Logan BK: Development and validation of a liquid chromatography-tandem mass spectrometry method for the identification and quantification of JWH-018, JWH-073, JWH-019, and JWH-250 in human whole blood. J Anal Toxicol 2011, 35:386–393.
32. Kavanagh P, Grigorov P, Melnik A, Savchuk S, Simonov A, Rozhanets V: Detection and tentative identification of urinary phase I metabolites of phenylethylindole cannabinimetabolites JWH-203 and JWH-251, by GC-MS and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2013, 934:102–108.
33. Kneisel S, Auwaerter V: Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction. J Mass Spectrom 2012, 47:825–835.
34. Lua IA, Lin SL, Lin HR, Lua AC: Replacing immunosassays for mephedrone, ketamines and six amphetamine-type stimulants with flow injection analysis tandem mass spectrometry. J Anal Toxicol 2012, 36:575–581.
35. Middleberg RA, Homan J: Quantitation of amphetamine-type stimulants by LC-MS/MS. Methods Mol Biol 2012, 902:105–114.
36. Shanks KG, Behonick GS, Dahn T, Terrell A: Identification of Novel Third-Generation Synthetic Cannabinoids in Products by Ultra-Performance Liquid Chromatography and Time-of-Flight Mass Spectrometry. J Anal Toxicol 2013, 37:517–525.
37. Sundstrom M, Pelander A, Angerer V, Hutter M, Kneisel S, Ojanpera I: A high-sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC-HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine. Anal Bioanal Chem 2013, 405:8603–8614.
38. Swartwood MJ, Boland DM, DeCantis AP: Determination of 32 cathinone derivatives and other designer drugs in serum by comprehensive LC-QQQ-MS/MS analysis. Anal Bioanal Chem 2013, 405:1383–1397.
39. Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Liu HF, Huebster MA: First Metabolic Profile of XLR-11, a Novel Synthetic Cannabinoid, Obtained by Using Human Hepatocytes and High-Resolution Mass Spectrometry. Clin Chem 2013, 59:1638–1648.
41. Apollonio LG, Whitall IR, Panca DJ, Kyt JM, Maher WA: Matrix effect and cross-reactivity of select amphetamine-type substances, designer analogues, and putrefactive amines using the Bio-Quant direct ELISA presumptive assays for amphetamine and methamphetamine. J Anal Toxicol 2007, 31:208–213.

42. Keimian S, Mellon MB, Banuelos S, Arndt C: Evaluation of commercial enzyme-linked immunosorbent assays to identify psychedelic phenethylamines. J Anal Toxicol 2011, 35:446–451.

43. Nakanishi K, Miki A, Zaitku K, Kamata H, Shima N, Kamata T, Katagi M, Tatsuno M, Tsuichihashi H, Suzuki K: Cross-activities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View, and the EmitR tests for use in drug enforcement. Forensic Sci Int 2008, 177:7–89.

44. Petrie M, Lynch KL, Binks S, Chang JS, Goetz RJ, Wu AH, Kraowski MD: Cross-reactivity studies and predictive modeling of “Bath Salts” and other amphetamine-type stimulants with amphetamine screening immunoassays. Clin Toxicol (Phila) 2013, 51:83–91.

45. Swortwood MJ, Heam WL, Decaprio AP: Cross-reactivity of designer drugs, including cathinone derivatives, in commercial enzyme-linked immunosorbent assays. In press.

46. Amsden O, Ofsa B, Lancaster D, Simon JR, McMullin M, Logan B: Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens. J Anal Toxicol 2013, 37:284–290.

47. Kraowski MD, Pizon AF, Siam MG, Giannoutsos S, Iyer M, Ekins S: Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. BMC Emerg Med 2009, 9:5.

48. Kraowski MD, Siam MG, Iyer M, Pizon AF, Giannoutsos S, Ekins S: Chemoinformatic methods for predicting interference in drug of abuse/toxicology immunoassays. Clin Chem 2009, 55:1203–1213.

49. Kraowski MD, Siam MG, Iyer M, Ekins S: Molecular similarity methods for predicting cross-reactivity with therapeutic drug monitoring immunoassays. Ther Drug Monit 2009, 31:337–344.

50. Muchmore SW, Debe DA, Metz JF, Brown SP, Martin YC, Hajduk PJ: Application of belief theory to similarity data fusion for use in analog searching and lead hopping. J Chem Inf Model 2008, 48:941–948.

51. Hert J, Willett P, Wilton DJ, Acklin P, Azzaoui K, Jacoby E, Schuffenhauer A: Comparison of fingerprint-based methods for virtual screening using multiple bioactive reference structures. J Chem Inform Comput Sci 2004, 44:1177–1185.

52. Hert J, Willett P, Wilton DJ, Acklin P, Azzaoui K, Jacoby E, Schuffenhauer A: Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures. Org Biomol Chem 2004, 2:3256–3266.

53. Seal A, Yogeeswari P, Srinivas D, Consortium O, Wild DJ: Enhanced ranking of Pk9 inhibitors using data fusion methods. J Cheminform 2013, 5:2.

54. Willett P: Combination of similarity rankings using data fusion. J Chem Inf Model 2013, 53:1–10.

55. Swamidass SJ, Azencott CA, Daily K, Baldi P: A CROC stronger than ROC: measuring, visualizing and optimizing early retrieval. Bioinformatics 2010, 26:1348–1356.

56. Eswald AH, Peters FT, Weise M, Maurer HH: Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gas chromatography–mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 824:123–131.

57. Kamata HT, Shima N, Zaitku K, Kamata T, Miki A, Nishikawa M, Katagi M, Tsuichihashi H: Metabolism of the recently encountered designer drug, methylone, in human and rats. Xenobiotica 2006, 36:709–723.

58. Lopez-Arzau R, Martinez-Clemente J, Carbo M, Pubill D, Escudebo E, Carnasa J: An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as “bath salts”, Prog Neuropsychopharmacol Biol Psychiatry 2013, 45:64–72.

59. Maurer HH, Kraemer T, Springer D, Stack RF: Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit 2004, 26:127–131.

60. Meyer NR, Wilhelm J, Peters FT, Maurer HH: Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography–mass spectrometry. Anal Bioanal Chem 2010, 397:1225–1233.

61. Staaab RF, Maurer HH: Metabolism of designer drugs of abuse. Curr Drug Metab 2005, 6:259–274.

62. Zaitku K, Katagi M, Kamata T, Kamata H, Shima N, Tsuichihashi H, Hayashi T, Kuroki H, Motoba R: Determination of a newly encountered designer drug “p-methoxethylamphetamine” and its metabolites in human urine and blood. Forensic Sci Int 2008, 177:7–84.

63. Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL: Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 2011, 6:e21917.

64. Chimalakonda KC, Moran CL, Kennedy PD, Endres GW, Uzebelo A, Dobrowolski PJ, Fifer EK, Lapoint J, Nelson LS, Hoffman RS, James LP, Radominska-Pandya A, Moran JH: Solid-phase extraction and quantitative measurement of omega-1 and omega-1 metabolites of JWH-018 and JWH-073 in human urine. Anal Chem 2011, 83:6381–6388.

65. Chimalakonda KC, Seeley KA, Bratton SM, Brents LR, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH: Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Space: identification of novel cannabinoid receptor ligands. Drug Metab Dispos 2012, 40:2174–2184.

66. Jang M, Yang W, Choi H, Chang H, Lee S, Kim E, Chung H: Monitoring of urinary metabolites of JWH-018 and JWH-073 in legal cases. Forensic Sci Int 2013, 231:13–19.

67. Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciské FK, Kramer JR, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, Prather PL, James LP, Radominska-Pandya A, Moran JH: Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem 2011, 83:4228–4236.

68. Sobolevsky T, Praslov I, Rodchenkov G: Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci Int 2010, 201:141–147.

69. Wohlfarth A, Scheidweiler KB, Chen X, Liu HF, Huestis MA: Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. Anal Chem 2013, 85:3730–3738.

70. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almq S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z: Identification of an endogenous 2-monoglucocere, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995, 50:83–90.

71. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Ettinger A, Mechoulam R: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946–1949.

72. Gomella LG, Hain S, Adams AG, Smith KM: Clinician’s pocket drug reference 2008. New York: McGraw-Hill Companies; 2008.

73. Chang C, Bahadjuri PM, Polie JF, Swaan PW, Ekins S: Rapid identification of novel P-glycoprotein ligands. Drug Metab Dispos 2006, 34:1976–1984.

74. Ekins S, Johnston JS, Bahadjuri P, D’Souza VM, Ray A, Chang C, Swaan PW: In vitro and pharmacophore-based discovery of novel PgpET1 inhibitors. Pharmaceut Res 2005, 22512–517.

75. Bender A, Glen RC: Molecular similarity: a key technique in molecular informatics. Org Biomol Chem 2004, 2:3204–3218.

76. Ekins S, Mestres J, Testa B: In silico pharmacology for drug discovery: applications to targets and beyond. Br J Pharmacol 2007, 152:21–37.

77. Krome AS, Patil SP, Kumar PP, Pradeep HH, Sastry CN: Virtual screening in drug discovery - a computational perspective. Curr Protein Pept Sci 2007, 8:329–351.

78. Obuchowski NA, Lieber ML, Wians FH Jr: ROC curves in clinical chemistry: uses, misuses, and possible solutions. Clin Chem 2004, 50:118–125.